Why the study?
Early identification of cardiac risk is essential for reducing late-stage attrition in drug development.
Does a calcium transient high-throughput assay in hiPSC-CMs accurately predict drug-induced acute cardiac hazard?
Does a calcium transient high-throughput assay in hiPSC-CMs accurately predict drug-induced acute cardiac hazard?
A calcium transient high-throughput assay in hiPSC-CMs accurately predicts drug-induced acute cardiac hazard with >95% sensitivity and specificity, supporting its use in early drug discovery.
Answers are grounded in this paper and cite their sources.
May aid early drug screening for QT/TdP risk; leaves open clinical and regulatory validation.
Introduction: Early identification of cardiac risk is essential for reducing late-stage attrition in drug development. We adapted the previously published cardiac hazard risk-scoring system using a calcium transient assay in human stem cell-derived CMs for the identification of cardiac risks recorded from the new hiPSC-CM line and investigated its predictivity and translational value based on the screening of a large number of reference and proprietary compounds. Methods: Evaluation of 55 reference drugs provided the translation of various pharmacological effects into a single hazard label (no, low, high, or very high hazard) using a Ca2+-sensitive fluorescent dye assay recorded by -by FDSS/µCell Functional Drug Screening System (Hamamatsu on hiPSC-CM line (FCDI iCell Cardiomyocytes2). Results: Application of the adapted hazard scoring system in the Ca2+ transient assay, using a second hiPS-CM line, provided comparable scoring results and predictivity of hazard, to the previously published scoring approach, with different pharmacological drug classes, as well as screening new chemical entities (NCE’s) using a single hazard label from four different scoring levels (no, low, high, or very high hazard). The scoring system results also showed minimal variability across three different lots of hiPSC-CMs, indicating good reproducibility of the cell line. The predictivity values (sensitivity and specificity) for drug-induced acute cardiac risk for QT-interval prolongation and Torsade de pointes (TdPs) were >95% and statistical modeling confirmed the prediction of proarrhythmic risk. The outcomes of the NCEs also showed consistency with findings in other well-established in vitro and in vivo cardiac risk assays. Conclusion: Evaluation of a large list of reference compounds and internal NCEs has confirmed the applicability of the adaptations made to the previously published novel scoring system for the hiPSC-CMs. The validation also established the predictivity for drug-induced cardiac risks with good translation to other established preclinical in vitro and in vivo assays, confirming the application of this novel scoring system in different stem cell-CM lines for early cardiac hazard identification.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: